Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4849-4857

  Youn, Cha Kyung ^a   Kim, Mi Hwa ^a   Cho, Hyun Ju ^a   Kim, Hong Beum ^a   Chang, In Youb ^a   Chung, Myung Hee ^b   You, Ho Jin ^a  

^a Chosun University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GENE PRODUCT; OXALIPLATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NIH 3T3 CELLS; ONCOGENE PROTEIN P21(RAS); ORGANOPLATINUM COMPOUNDS; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSFECTION; UP-REGULATION;

EID: 3142773418     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0348     Document Type: Article

References (51)

1. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997;7:75-9.
2. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 2002;192:125-30.
3. White MA, Nicolette C, Minden A, et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995;80:533-41.
4. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
5. Sklar MD. Increased resistance to cis-diamminedichloroplatinum(II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res 1988;48:793-7.
6. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH3T3 cells to ionizing radiation. Science 1988;239:645-7.
7. Isonishi S, Hom DK, Thiebaut FB, et al. Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res 1991;51:5903-9.
8. Hermens AF, Bentvelzen PA. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res 1992;52:3073-82.
9. Levy E, Baroche C, Barrer JM, et al. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA crosslinks and their repair. Carcinogenesis 1994;15:845-50.
10. Fan J, Banerjee D, Stambrook PJ, Bertino JR. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem Pharmacol 1997;53:1203-9.
11. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Ddirect evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-600.
12. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes. Anticancer Drugs 2000;11:225-36.
13. Cho HJ, Jeong HG, Lee JS, et al. Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem 2002;277:19358-66.
14. O'Dwyer PJ, Hamilton TC, Johnson SW. In: V. J. DeVita, Principles and practice of oncology, Cisplatin and its analogue. Philadelphia: J. B. Lippincott, 1997. p. 418-32.
15. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
16. Crul M, Schellens JH, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997;23:341-66.
17. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev 1998;24:331-44.
18. Suo Z, Lippard SJ, Johnson KA. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry 1999;38:715-26.
19. Batty DP, Wood RD. Damage recognition in nucleotide excision repair of DNA. Gene 2000;241:193-204.
20. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups I and III. Carcinogenesis 1993;14:2177-80.
21. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996;66:779-83.
22. Dunkern TR, Fritz G, Kaina B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair. Mutat Res 2001;486:249-58.
23. Mu D, Park CH, Matsunaga T, Hsu DS, Reardon JT, Sancar A. Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 1995;270:2415-8.
24. Aboussekhra A, Biggerstaff M, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995;80:859-68.
25. Lee MR, Kim SH, Cho HJ, et al. Transcription factors NF-YA regulate the induction of human OGG1 following DNA-alkylating agent methylmethane sulfonate (MMS) treatment. J Biol Chem 2004;279:9857-66.
26. Sancar A. DNA excision repair. Annu Rev Biochem 1996;65:43-81.
27. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-84.
28. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
29. Kinashi Y, Akaboshi M, Masunaga S, Ono K, Watanabe M. Resistance to 195mPt-radiolabeled cis-diaminedichloroplatinum (II) of SHOK cells transfected with various oncogenes. Radiat Med 1998;16:233-7.
30. Yen L, Nie ZR, You XL, Richard S, Langton-Webster BC, Alaoui-Jamali MA. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. Oncogene 1997;14:1827-35.
31. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:3419-25.
32. Li Q, Tsang B, Bostick-Bruton F, Reed E. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 1999;57:347-53.
33. Li Q, Zhang L, Tsang B, Gardner K, Bostick-Bruton F, Reed E. Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells. Cell Mol Life Sci 1999;55:456-66.
34. Abate C, Patel L, Rauscher FJ, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990;249:1157-61.
35. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
36. Xiao L, Lang W. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Cancer Res 2000;60:400-8.
37. Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990;265:11285-8.
38. Gjerset RA, Lebedeva S, Haghighi A, Turla ST, Mercola D. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ 1999;10:545-54.
39. Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997;272:14041-4.
40. Zhao R, Rabo YB, Egyhazi S, et al. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Anticancer Drugs 1995;6:657-68.
41. Moorehead RA, Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000;59:337-45.
42. Potapova O, Basu S, Mercola D, Holbrook NJ. Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem 2001;276:28546-53.
43. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997;57:850-6.
44. Sheibani N, Jennerwein MM, Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 1989;28:3120-4.
45. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 1999;284:958-61.
46. Melton DW, Ketchen AM, Nunez F, et al. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998;111:395-404.
47. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8.
48. Metzger R, Metzger R, Leichman CG, et al L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
49. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63:1311-6.
50. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
51. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.